![male scientist in laboratory male scientist in laboratory](/sites/default/files/us/corporate_images/rd_045.jpg)
![folded bandages folded bandages](/sites/default/files/us/Images/press-release-holding-image03.jpg)
PRESS RELEASE 15 Oct 2021 at 17:55
U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
![newspapers stacked on top of news sign newspapers stacked on top of news sign](/sites/default/files/us/Images/press-release-holding-image02.jpg)
PRESS RELEASE 14 May 2019 at 08:35
Boehringer Ingelheim announces resolution of Cyltezo® patent litigation
![](/sites/default/files/us/press_images/2017/cyltezo-logo-sm.jpg)
PRESS RELEASE 29 Aug 2017 at 09:13
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases
![newspapers stacked on top of news sign newspapers stacked on top of news sign](/sites/default/files/us/Images/press-release-holding-image02.jpg)
PRESS RELEASE 27 Jul 2017 at 09:10